
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care has demonstrated a solid revenue trajectory, with projected revenue increases reaching approximately $1.229 million by 2027. The firm's strategic growth is indicated by an expected return to positive new patient start (NPS) growth in the US, driven by increased conversions from multiple daily injections and improved pharmacy access. Additionally, revenue beat expectations due to significant traction in the pharmacy channel, alongside a noted increase in renewal shipments, contributing to robust overall financial performance.
Bears say
Tandem Diabetes Care has faced significant operating losses since its inception and does not provide assurance for sustained profitability, casting doubt on its future financial health. The company's outlook is further challenged by expectations of flat to slightly declining new patient starts in the U.S. market, coupled with potential risks from competitive pressures and the performance of new product launches like the Mobi pump. Additionally, the company reported a 4% year-over-year decline in U.S. pump shipments, along with lower growth and margins compared to industry peers, which exacerbates concerns over its profitability and market position.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares